European Journal of Medicinal Chemistry p. 562 - 575 (2019)
Update date:2022-08-30
Topics:
Yan, Zhiqiang
Chong, Shuyi
Lin, Huiyun
Yang, Qian
Wang, Xin
Zhang, Weidong
Zhang, Xiaokun
Zeng, Zhiping
Su, Ying
Nuclear receptor RXRα plays an important role in many biological and pathological processes. The nongenomic action of RXRα is implicated in many cancers. K-8008, a non-canonical RXRα ligand derived from sulindac, inhibits the TNFα-activated PI3K/AKT pathway by mediating the interaction between a truncated form of RXRα (tRXRα) and the p85α regulatory subunit of PI3K and exerts potent anticancer activity in animal model. Herein we report our studies of a novel series of K-8008 analogs as potential anticancer agents targeting RXRα. Two compounds 8b and 18a were identified to have slightly stronger binding to RXRα and improved apoptotic activities in breast cancer cells.
View MoreHangzhou Pharma & Chem Co.,Ltd.
Contact:+86-571-87040515
Address:No,139Qingchun Rd
Nanjing Habo Medical Technology Co., Ltd.
Contact:025-85769882
Address:No.108. Ganjiabian east. Qixia District .Nanjing
Hebei Lead Bio-Chemicals Co., Ltd.
website:http://www.ldbiochem.com
Contact:+86-311-87826503
Address:481, Heping West Road, Shijiazhuang,China
Jintan Jinnuo Chemical Co., Ltd.
Contact:+86-519-80199901
Address:Room 1804, Building 1, Huacheng Business Plaza, Jintan, Jiangsu, China
Quzhou Ruiyuan chemical Co., Ltd
Contact:+86-570-3039321/3039361/3039308
Address:18# Huayang Road,Quzhou High-tech Industrial Park, Zhejiang China.
Doi:10.1007/BF00497211
(1990)Doi:10.1021/acs.orglett.6b02301
(2016)Doi:10.1016/j.tetlet.2007.07.018
(2007)Doi:10.1021/jp9609500
(1997)Doi:10.1021/acscatal.1c02140
(2021)Doi:10.1021/jo01273a080
(1968)